** Morgan Stanley downgrades rating on telehealth firm Hims and Hers HIMS.N to "equal weight" from "overweight"
** HIMS shares down marginally at $60.35 premarket
** "While HIMS checks a lot of boxes we evaluate for an investment thesis ... meaningful outperformance in the stock raises the bar near term" - brokerage
** Stock has been trading at record highs in recent days and has risen 150% so far in 2025
** MS points to investor optimism over the company's business of selling compounded versions of GLP-1 weight-loss injections, such as Novo Nordisk's NOVOb.CO Wegovy, as driving the recent gains in stock
** MS also raised PT to $60 from $42
** 7 of 16 brokerages rate the stock "buy" or higher, 7 "hold" and 2 "sell" or lower; their median PT is $26 - LSEG data
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。